Cell & Gene Therapy · Rare Disease Therapeutics
Editas Medicine news and milestones
Editas Medicine: 7 headlines on record, 1 headline in the last 90 days. Its story counts 2 milestones.
Data updated Nov 14, 2026 · Back to the company report
7Headlines
1In 90 days
2Milestones
Headlines
Sep 12026
News · markets.businessinsider.com
CAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developi...
Jun 28, 20252025
News · The Motley Fool
Wall Street Expects Editas Medicine to Soar 53%. Is It Time to Buy Now?
May 14, 20252025
News · Nasdaq
Explore the exciting world of Editas Medicine (NASDAQ: EDIT) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights…
Dec 13, 20242024
Sep 25, 20242024
News · seekingalpha.com
Jan 15, 20242024
News · The Motley Fool
The past few years have been difficult ones, but shares of the gene editor are far more attractive now that a CRISPR medicine has passed regulatory hurdles.
Jan 5, 20162016
Sources: the outlets named on each headline, each story once
Milestones
2025
Team shrank to 109 was 294 · US Form 5500 (plan participants)
1986
Founded
Each milestone is dated by its source: registers, filings, the press
How to cite
Editas Medicine, News. Alion, Nov 14, 2026. https://alion.io/company/editasmedicine/news